Serum interleukin-17 & nitric oxide levels in patients with primary Sjögren's syndrome

Indian Journal of Medical Research

Volumn 135, Issue 4, 2012, Pages 513-519

  Miletic M ^a   Stojanovic R ^b   Pajic O ^b   Bugarski, D ^a   Mojsilovic S ^a   Cokic V ^a   Milenkovic P ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Interleukin 17; Nitric oxide; Primary Sj gren's syndrome; Rheumatoid arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; INTERLEUKIN 17; METHOTREXATE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOFLUORESCENCE TEST; LOW DRUG DOSE; MALE; NEUROPATHY; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN DISEASE; AGED; BLOOD; MIDDLE AGED;

AGED; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN-17; MIDDLE AGED; NITRIC OXIDE; RHEUMATOID FACTOR; SJOGREN'S SYNDROME;

EID: 84871855530     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 2007; 51: 1139-1147.
2. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 1998; 161: 6383-6389.
3. Jovčić G, Bugarski D, Petakov M, Stanković J, Stojanović N, Milenković P. Effects of IL-17 on in vitro hematopoietic progenitor cells growth and cytokine release in normal and post-irradiated murine bone marrow. Growth Factors 2001; 19: 61-71.
4. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
5. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008; 41: 84-91.
6. Miljković D, Trajković V. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev 2004; 15: 21-32.
7. Peranzoni E, Marigo I, Dolcetti L, Ugel S, Sonda N, Taschin E, et al. Role of arginine metabolism in immunity and immunopathology. Immunobiology 2007; 212: 795-812.
8. Nagy G, Clark JM, Buzás EI, Gorman CL, Cope AP. Nitric oxide, chronic inflammation and autoimmunity. Immunol Lett 2007; 111: 1-5.
9. Wanchu A, Khullar M, Sud A, Bambery P. Elevated nitric oxide production in patients with primary Sjögren's syndrome. Clin Rheumatol 2000; 19: 360-364.
10. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009; 175: 1167-1177.
11. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome: potential therapeutic targets. Ann Rheum Dis 2010; 69: 945-948.
12. Becker H, Pavenstaedt H, Willeke P. Emerging treatment strategies and potential therapeutic targets in primary Sjögren's syndrome. Inflamm Allergy Drug Targets 2010; 9: 10-19.
13. Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB. IL17: potential therapeutic target in Sjögren's syndrome using adenovirus-mediated gene transfer. Lab Invest 2011; 91: 54-62.
14. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, et al. Assessment of the Europen classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The Europen Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis 1996; 55: 116-121.
15. Cabiedes J, Núñnex-Álvarez CA. Antinuclear antibodies. Reumatol Clin 2010; 6: 224-230.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
17. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008; 58: 734-743.
18. Mariette X, Gottenberg JE. Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010; 22: 471-477.
19. Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008; 35: 515-519.
20. Zwerina J, Redlich K, Polzer K, Joosten L, Krönke G, Distler J, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104: 11742-11747.
21. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172: 146-155.
22. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385-393.
23. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573.
24. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.
25. Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA. Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome. Rheumatology (Oxford) 2009; 48: 1102-1106.
26. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10: 778-785.
27. Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 2005; 17: 558-565.
28. Wanchu A, Khullar M, Sud A, Deodhar SD, Bambery P. Elevated urinary nitrite and citrulline levels in patients with rheumatoid arthritis. Inflammopharmacology 1999; 7: 155-161.
29. Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998; 18: 41-43.
30. Caulfield VL, Balmer C, Dawson LJ, Smith PM. A role for nitric oxide-mediated glandular hypofunction in a nonapoptotic model for Sjögren's syndrome. Rheumatology (Oxford) 2009; 48: 727-733.
31. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β- converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 1997; 185: 601-607.
32. Fehsel K, Krancke KD, Meyer KL, Huber H, Wahn V, Kolb-Bachofen V. Nitric oxide induces apoptosis in mouse thymocytes. J Immunol 1995; 155: 2858-2865.
33. Manganelli P, Fietta P. Apoptosis and Sjögren syndrome. Semin Arthritits Rheum 2003; 33: 49-65.
34. Ping L, Ogawa N, Sugai S. Novel role of CD40 in Fasdependent apoptosis of cultured salivary epithelial cells from patients with Sjögren's syndrome. Arthritis Rheum 2005; 52: 573-581.
35. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87: 10043-10047.
36. Niedbala W, Cai B, Liew FY. Role of nitric oxide in the regulation of T cell functions. Ann Rheum Dis 2006; 65 (Suppl 3): iii37-iii40.